Ligand Information
| Ligand General Information | Top | |||
|---|---|---|---|---|
| Ligand ID |
LB0JL5
|
|||
| Ligand Name |
2-(Cyclobutylamino)-N-[(2s)-3-(3,4-Dihydroisoquinolin-2(1h)-Yl)-2-Hydroxypropyl]pyridine-4-Carboxamide
|
|||
| Synonyms |
1616391-87-7; GSK591; EPZ015866; GSK3203591; (S)-2-(Cyclobutylamino)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)isonicotinamide; 2-(cyclobutylamino)-N-[(2S)-2-hydroxy-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)propyl]pyridine-4-carboxamide; 2-(CYCLOBUTYLAMINO)-N-[(2S)-3-(3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-2-HYDROXYPROPYL]PYRIDINE-4-CARBOXAMIDE; 2-(Cyclobutylamino)-N-[(2s)-3-(3,4-Dihydroisoquinolin-2(1h)-Yl)-2-Hydroxypropyl]pyridine-4-Carboxamide; EPZ015866;GSK3203591; GTPL8954; CHEMBL4542380; SCHEMBL16220740; BDBM178085; EX-A1117; MFCD30187524; s8111; AKOS030526610; ZINC521836465; CCG-268410; CS-5643; EPZ-015866; NCGC00483168-01; AC-35340; AS-74824; GSK591, >=97% (HPLC); HY-100235; A14374; A901563; US9675614, 188; GSK591 (EPZ015866,GSK3203591); GSK591; EPZ015866; GSK3203591; Q27077914; 2-(Cyclobutylamino)-N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-hydroxypropyl]-4-pyridinecarboxamide;GSK591; 4-Pyridinecarboxamide, 2-(cyclobutylamino)-N-[(2S)-3-(3,4-dihydro-2(1H)-isoquinolinyl)-2-hydroxypropyl]-; 4Z2
Click to Show/Hide
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28N4O2
|
|||
| Canonical SMILES |
C1CC(C1)NC2=NC=CC(=C2)C(=O)NCC(CN3CCC4=CC=CC=C4C3)O
|
|||
| InChI |
1S/C22H28N4O2/c27-20(15-26-11-9-16-4-1-2-5-18(16)14-26)13-24-22(28)17-8-10-23-21(12-17)25-19-6-3-7-19/h1-2,4-5,8,10,12,19-20,27H,3,6-7,9,11,13-15H2,(H,23,25)(H,24,28)/t20-/m0/s1
|
|||
| InChIKey |
TWKYXZSXXXKKJU-FQEVSTJZSA-N
|
|||
| PubChem Compound ID | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.